 Kazia Therapeutics Limited ASX: KZA; NASDAQ: KZIA, an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib formerly GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. 